key: cord-0999174-duj99sg9
authors: Chauss, Daniel; Freiwald, Tilo; McGregor, Reuben; Yan, Bingyu; Wang, Luopin; Nova-Lamperti, Estefania; Kumar, Dhaneshwar; Zhang, Zonghao; Teague, Heather; West, Erin E; Vannella, Kevin M; Ramos-Benitez, Marcos J; Bibby, Jack; Kelly, Audrey; Malik, Amna; Freeman, Alexandra F; Schwartz, Daniella M; Portilla, Didier; Chertow, Daniel S; John, Susan; Lavender, Paul; Kemper, Claudia; Lombardi, Giovanna; Mehta, Nehal N; Cooper, Nichola; Lionakis, Michail S; Laurence, Arian; Kazemian, Majid; Afzali, Behdad
title: Autocrine Vitamin D-signaling switches off pro-inflammatory programs of Th1 cells
date: 2022-01-01
journal: Nat Immunol
DOI: 10.1038/s41590-021-01080-3
sha: 0ce8493854e0f4e37aad9deb003351c6f78f7379
doc_id: 999174
cord_uid: duj99sg9

The molecular mechanisms governing orderly shutdown and retraction of CD4(+) T helper (Th)1 responses remain poorly understood. Here, we show that complement triggers contraction of Th1 responses by inducing intrinsic expression of the vitamin D (VitD) receptor (VDR) and the VitD-activating enzyme CYP27B1, permitting T cells to both activate and respond to VitD. VitD then initiated transition from pro-inflammatory IFN-γ (+) Th1 cells to suppressive IL-10(+) cells. This process was primed by dynamic changes in the epigenetic landscape of CD4(+) T cells, generating super-enhancers and recruiting several transcription factors, notably c-JUN, STAT3 and BACH2, which together with VDR shaped the transcriptional response to VitD. Accordingly, VitD did not induce IL-10 in cells with dysfunctional BACH2 or STAT3. Bronchoalveolar lavage fluid CD4(+) T cells of COVID-19 patients were Th1-skewed and showed de-repression of genes down-regulated by VitD, either from lack of substrate (VitD deficiency) and/or abnormal regulation of this system.

A significant number of patients with COVID-19 develop severe and life-threatening hyper-inflammation and acute respiratory distress syndrome (ARDS). Mortality from severe COVID-19 remains high, in part due to the limited range of specific immunomodulatory therapies available. Survivors, and those with milder disease, may lose significant tissue function from persistent inflammation and fibrosis, causing chronic lung disease. The efficacy of dexamethasone in reducing mortality indicates the importance of inflammation to disease severity 1 . Improved understanding of the basic mechanisms of COVID-19 will aid rational drug design to reduce morbidity and mortality.

Pro-inflammatory immune responses are necessary for pathogen clearance but cause severe tissue damage if not shut down in a timely manner 2 . The complement system is instrumental in pathogen clearance via recruitment and activation of immune cells 3 . Briefly, complement (C)3, a pro-enzyme, is activated in response to pathogen-or danger-sensing (the lectin pathway), immune complexes (classical pathway) or altered self (alternative pathway) to generate active C3a and C3b fragments, which recruit and activate immune cells and instigate activation of downstream complement components 4 . Complement activation is a pathophysiological feature of ARDS of many etiologies 5 and mediates acute lung injury driven by respiratory viruses 6 . Circulating concentrations of activated complement fragments are high in COVID-19, correlate with severity and are independently associated with mortality 7, 8 . Polymorphisms in complement regulators are, likewise, risk factors for poor outcomes 9 . Animal models of other beta-coronaviruses have indicated complement as part of a pathologic signature of lung injury that can be ameliorated by complement inhibition 10 . Emerging clinical trial evidence, from small numbers of treated patients, also points to potential benefits of complement targeting in COVID-19 11 .

The complement system is both hepatocyte-derived and serum-effective, but also expressed and biologically active within cells. Notably, activated CD4 + T cells process C3 intracellularly to C3a and C3b via Cathepsin L (CTSL)-mediated cleavage 12 . We have recently shown that SARS-CoV2-infected respiratory epithelial cells express and process C3 intracellularly via a cell-intrinsic enzymatic system to C3a and C3b 13 . This represents a source of local complement within SARS-CoV2-infected lungs, where plasma-derived complement is likely to be absent, and signifies the lung epithelial lining as a complementrich micro-environment. Excessive complement and IFN-γ-associated responses are both known drivers of tissue injury and immunopathogenesis 14, 15 . On CD4 + T cells, C3b binds CD46, its canonical receptor, to sequentially drive T helper (Th)1 differentiation followed by their shut-down, represented by initial production of IFN-γ alone, then IFN-γ together with IL-10, followed by IL-10 alone 16 . Expression of IL-10 by Th1 cells is a critical regulator of Th1 associated inflammation 2 . However, the exact molecular mechanisms governing orderly regulation of Th1 responses culminating in IL-10 expression remain poorly understood and may be critical in the recovery phase of COVID-19 and other Th1-mediated inflammatory diseases.

Vitamin D (VitD) is a fat-soluble pro-hormone carefully regulated by enzymatic activation and inactivation. Most VitD is synthesized in the skin on exposure to ultraviolet B (UVB) radiation from sunlight, then undergoes sequential hydroxylation to 25(OH)VitD and 1,25(OH) 2 VitD, classically in the liver and kidneys, respectively. VitD has immunomodulatory functions, hence, VitD deficiency is associated with adverse outcomes in both infectious 17 and autoimmune diseases 18 . There are compelling epidemiological associations between incidence and severity of COVID-19 and VitD deficiency/insufficiency 19 , but the molecular mechanisms remains unknown.

We found Th1-skewed CD4 + T cell responses in bronchoalveolar lavage fluid (BALF) of COVID-19 patients. As this is a complement-rich microenvironment, we investigated the molecular mechanisms governing orderly shutdown of Th1 responses induced by CD46 engagement. We found that CD46 induces a cell-intrinsic VitD signaling, enabling T cells to both fully activate and respond to VitD. This process was primed by epigenetic remodeling and recruitment of four key transcription factors (TFs), vitamin D receptor (VDR), c-JUN, STAT3 and BACH2. Lastly, we examined these pathways in CD4 + T cells from the BALF of SARS-CoV2-infected patients and found it to be impaired.

We analyzed single cell RNAseq (scRNAseq) data from the BALF and PBMC of COVID-19 patients and healthy controls (GSE145926, GSE122960 and GSE150728). Because immunity to both SARS-CoV1 and MERS-CoV is mediated by, amongst other cells, IFN-γproducing CD4 + memory T cells 20 and development of Th1-polarized responses in SARS-CoV2 infection 21 is suspected to contribute to pathogenic hyper-inflammation, we focused our analyses on CD4 + T cells. T cell populations within BALF (Extended Data Fig.1a -b) comprised 5 major sub-clusters, including CD4 + Th cells, according to well-characterized markers (Figs. 1a and Extended Data Fig.1c) . Although the proportion of T cells that were CD4 + did not differ between patients and controls (Figs. 1a and Extended Data Fig.1d) , 312 genes were upregulated and 134 genes downregulated in patient CD4 + T cells ( Fig. 1b and Table S1a ). These differentially expressed genes (DEGs) were enriched in noteworthy biological pathways, including interferon-γ response and complement ( Fig. 1c and Table  S1b ). Examination of transcriptional programs by module score indicated that CD4 + T cells in patients were preferentially polarized towards Th1, as opposed to Th2 or Th17 lineages (Fig. 1d) . Consistently, expression of core Th1 marker genes were higher in patients (Fig.  1e ).

Enrichment of complement pathway (Fig. 1c ) was notable because a) we recently identified complement as one of the most highly induced pathways in lung CD4 + T cells 22 ; b) SARS-CoV2 potently induces complement, especially complement factor 3 (C3), from respiratory epithelial cells 13 ; c) COVID-19 lungs are a complement-rich micro-environment 23 ; and d) CD4 + T lymphocytes in COVID-19 lungs have a CD46-activated signature 13 . Because CD46 drives both Th1 differentiation and shutdown, characterized by IFN-γ and IL-10 expression, respectively 16 , we determined the state of Th1 cells in COVID-19 BALF. IL10 mRNA was dropped out in scRNAseq, but detectable in bulk RNAseq from BALF (Extended Data Fig.1e ). Consistently we observed significant enrichment of Th1-related genes in patient cells compared to controls, but ~5-fold lower IL10 (Extended Data   Fig.1e ). Similar examination within scRNAseq of PBMC (Extended Data Figs.2a-b) did not show meaningful differences in Th1, Th2 or Th17 lineage genes (Extended Data Fig.2c ). Collectively, these data indicated the Th1 program and complement signature as features of Th cells at the site of pulmonary inflammation where virus-specific T cells may be concentrated 24 , and are consistent the notion that COVID-19 Th1 cells were in the inflammatory phase of their lifecycle compared to healthy controls.

Prolonged and/or hyper-Th1 activity is pathogenic 14, 15 . To discover how shutdown of Th1 cells could be accelerated, we explored how complement regulates Th1 shutdown in healthy cells. CD46, engaged by environmental or intracellularly-generated C3b, works co-operatively with T cell receptor signaling to drive Th1 differentiation then subsequent shutdown 16 . Thus, T cells activated with anti(α)-CD3 and α-CD46 produce IFN-γ, then co-produce IL-10 before shutting down IFN-γ to produce only IL-10 16 (Fig. 2a) . T cells secreting neither cytokine (IFN-γ − IL-10 − cells) are also appropriately activated as they upregulate activation markers (CD25 and CD69 -Extended Data Figs.3a-b) and proliferate (Extended Data Figs.3c-d). Because this CD46 system is not present in mouse T cells, we explored its function in human CD4 + T lymphocytes. Unless specified otherwise, we used Treg-depleted CD4 + Th cells (CD4 + CD25 − ) throughout. After α-CD3+α-CD46 activation, we flow-sorted cells from each quadrant by surface cytokine capture (Fig. 2a) and performed transcriptome analysis (Extended Data Figs.4a-c). Comparing transcriptomes of IFN-γ + IL-10 − , IFN-γ + IL-10 + and IFN-γ − IL-10 + against IFN-γ − IL-10 − Th cells, ~2000 DEGs were in common ( Fig. 2b and Extended Data Fig.4d and Tables S1c-d). These were enriched for proteins whose molecular function pertained to TF biology (Extended Data Figs.4e-f and 2c and Table S1e ), indicating that a key role of CD46 is to regulate TFs. In total, 24 TFs were induced by CD46 in cytokine producing CD4 + cells (Fig. 2d) , including VDR (Fig. 2d) . VDR was notable for two reasons. First, independent prediction of TFs regulating DEGs of BALF CD4 + T cells and lung biopsies of COVID-19 versus healthy donors returned VDR among the top candidates ( Fig. 2e and Table S1f ). Second, CYP27B1 was concurrently induced in the transcriptome data (Fig. 2d) . CYP27B1 is the 1α-hydroxylase catalyzing the final activation of VitD, converting 25(OH)VitD to biologically active 1,25(OH) 2 VitD. Inducible expression of CYP27B1 and VDR in Th cells indicated the likely presence of an autocrine/paracrine loop, whereby T cells can both activate and respond to VitD. Although both are described in activated T cells 25, 26 , the molecular mechanism and consequences are unknown. α-CD3+α-CD28 stimulation of T cells activates C3 processing intracellularly by CTSL, generating autocrine C3b to ligate CD46 on the cell surface 12 , which in turn enhances C3 processing to further generate C3b 12 . To establish that CYP27B1 and VDR are induced by complement, we confirmed that α-CD3+α-CD28 and α-CD3+α-CD46 both stimulate these genes in T cells and that this effect was nullified by a cell-permeable CTSL inhibitor, which blocks intracellularly-generated C3b (Fig. 2f) . Similarly, T cells from CD46-deficient patients did not upregulate CYP27B1 or VDR with either stimulus (Fig. 2g) . Collectively, these data indicated that CD46 ligation by complement induces both the enzyme and receptor to enable Th cells to fully activate and respond to VitD. and respond to VitD. We cultured similarly stimulated cells with inactive VitD and silenced CTSL, VDR or CYP27B1 using siRNA and assessed IL10 transcription. A significant reduction in IL10 was evident on silencing any of these components (Figs 2j and Extended Data Fig.5 ), indicating that they are all required for producing IL-10. Altogether, these data indicated existence of a novel complement-induced intracellular autocrine/paracrine VitD system promoting T cell shutdown.

We next investigated the effects of VitD on CD4 + T cells. In all subsequent experiments cells were activated with α-CD3 and α-CD28 (as this stimulus also signals through CD46 12 ), and we used active 1,25(OH) 2 VitD. We confirmed that VDR protein was induced by T cell activation (Extended Data Fig.6a ), VitD enhanced VDR expression 27 (Extended Data Fig.6a) , and VitD-bound VDR translocated to the nucleus (Extended Data Figs.6b-c). VitD upregulated 262 and downregulated 128 genes in Th cells ( Fig. 3a and Tables S2a-b), which were not due to alterations in cell proliferation or death (Extended Data Fig.6d ). Classical VitD-regulated genes, including CTLA4, CD38 and CYP24A1, were induced and both type 1 (IFNG) and type 17 (IL17A, IL17F, IL22 and IL26) cytokines were repressed (Figs. 3b-c), consistent with previous reports 28 . Genes induced by VitD included two cytokines, IL10 and IL6, and several TFs, including JUN, BACH2 and STAT3 (Figs. 3b-c). As IL-10-producing CD4 + FoxP3 − type 1 regulatory T (Tr1) cells can be induced from naïve Th cells by VitD 29 , we noted that genes induced/repressed by VitD were not enriched in Tr1 signature genes (Extended Data Fig.6e ) and did not exhibit the archetypal surface phenotype of Tr1 cells (CD49b + LAG3 +30 ) (Extended Data Fig.6f) . Similarly, FOXP3, the master TF of natural Tregs, was not upregulated by VitD (Table S2b) . Genes regulated by VitD were most significantly enriched for cytokines (Extended Data Fig.6g) . Unexpectedly, IL6, normally a pro-inflammatory cytokine, was the most highly induced gene in the hierarchy of cytokines regulated by VitD (Extended Data Fig.7a ). We confirmed repression of IFN-γ and IL-17 and induction of IL-10 and IL-6 proteins in VitD-treated Th cells (Extended Data Fig.7b ) and noted a strong dose-response relationship between VitD concentrations and these effects (Fig. 3d ). To confirm again the autocrine/paracrine VitD activation system at the protein level (Extended Data Fig.5c ), we observed repression of IFN-γ and IL-17 and induction of IL-10 and IL-6 by Th cells treated with only inactive 25(OH)VitD, indicating intracellular conversion of 25(OH)VitD to active 1,25(OH) 2 VitD (Extended Data Fig.7d ).

IL-6 is a pleiotropic cytokine expressed by most stromal and immune cells 31 . Yet it is not commonly attributed to CD4 + T cells. We established that IL6 mRNA and protein were produced by T cells and induced by VitD (Extended Data Fig.7e ) and that VitD treatment significantly increased intracellular expression of IL-6 (Extended Data Fig.7f ). In these experiments, there was a strong correlation between IL-6 and IL-10 produced in response to VitD (Fig. 3e) , suggesting a potential causal relationship. Accordingly, we stimulated Th cells with VitD, with or without Tocilizumab, an IL-6 receptor (IL-6R) blocking antibody used clinically to treat IL-6-dependent cytokine release syndrome, including that seen in COVID-19 32 . Tocilizumab significantly impaired IL-10 produced by VitD, indicating that IL-6R signaling induced by autocrine/paracrine IL-6 promotes IL-10 in VitD-treated Th cells (Fig. 3f) . IL-6 can cooperate with IL-27 33 or IL-21 34 to promote IL-10 production in mouse T cells. However, both these cytokines were repressed by VitD in our transcriptomic analyses (Table S2b) , so it did not appear likely that these cytokines cooperate with IL-6 to induce IL-10 in this setting. Addition of exogenous IL-6 without VitD did not induce IL-10 (Extended Data Fig.7g ) but increased pro-inflammatory IL-17 (Extended Data Fig.7h ), as has been reported 35 . These data indicate that pro-inflammatory functions of IL-6 may be restricted or averted by the production of anti-inflammatory IL-10 in the presence of VitD in human Th cells (Fig. 3f ).

Genes differentially expressed by VitD were enriched in cytokine signaling pathways, which are commonly mediated through phosphorylation of signal-dependent TFs, including JAK-STATs (Extended Data Fig.6g ). We therefore carried out a phospho-kinase protein array using lysates of carrier and VitD-treated cells. Five proteins showed significant differences in phosphorylation between carrier and VitD, most notably c-JUN and STAT3, both of which were significantly more phosphorylated (Figs. 3g-h and Extended Data Fig.7i ). Immunoblotting confirmed induction of both STAT3 protein and STAT3 phosphorylation by VitD ( Fig. 3i and Extended Data Fig.7j ). IL-6 potently drives STAT3 activation by phosphorylation 31 . STAT3 phosphorylation induced by VitD was abrogated by blockade of the IL-6R with Tocilizumab, indicating that VitD-induced IL-6 is responsible for STAT3 phosphorylation (Figs. 3i and Extended Data Fig.7j ). Conversely, STAT3 protein expression was dependent on VitD but independent of IL-6 signaling, since IL-6R blockade did not reverse its induction by VitD (Figs. 3i and Extended Data Fig.7j ). By contrast, both c-JUN expression and phosphorylation were dependent on VitD and mostly independent of IL-6 ( Fig. 3i and Extended Data Fig.7j ). As VitD-induced STAT3 phosphorylation was mediated by IL-6, we investigated whether STAT3 drives IL-10 produced by VitD. Both a cell permeable STAT3 inhibitor and knock-down of STAT3 by siRNA significantly impaired IL-10 produced in response to VitD (Figs. 3j-k and Extended Data Fig.7k-l) . Likewise, VitD failed to produce significant IL-10 from Th cells of patients with hyper-IgE syndrome, that have dominant negative STAT3 mutations and are unable to transduce STAT3 signaling normally (Fig. 3j) . Collectively, these data established that VitD induces STAT3 and IL-6, and autocrine/paracrine IL-6R engagement phosphorylates STAT3, which promotes production of IL-10.

VitD-bound VDR interacts with histone acetyl transferases, transcriptional co-activators, co-repressors, and chromatin remodeling complexes to modulate transcription. We explored the effects of VitD on T cells epigenetic landscapes, using memory CD4 + T cells (these cells express VDR without requiring pre-activation). We profiled genome-wide histone 3 lysine 27 acetylation (H3K27Ac), a marker of active regions of the genome, using cleavage under target and release using nuclease (CUT&RUN) in VitD and carrier-treated cells. VitD induced dynamic changes in histone acetylation genome-wide (Figs. 4a-b), indicating significant changes in enhancer architecture. By 48h after VitD treatment, ~25000 and ~21000 H3K27Ac peaks were induced and repressed, respectively (Figs. 4c-d and Table  S3a ). Loci of genes transcriptionally induced by VitD showed increased histone acetylation and those repressed by VitD had reduced histone acetylation (Fig. 4c) . The size of these peaks was significantly affected by VitD, leading to generation of new super-enhancer (SE) architectures and promotion of existing SEs (Fig. 4e) . SEs are complex regulatory domains comprised of collections of enhancers critical for regulating genes of particular importance to cell identity and risk of genetic disease 36, 37 . VitD-modified SEs included those associated with BACH2, STAT3, IL10 and other genes induced by VitD ( Fig. 4e and Table S3b ).

To identify potential TFs recruited to these loci, we carried out TF DNA motif finding at H3K27Ac peak loci induced by VitD. The top enriched motifs were VDR, AP-1 family members, notably c-JUN and BACH2, and STAT3 (Fig. 4f ). All three of these were TFs transcriptionally induced by VitD (Figs. 3b-c) and two of these, c-JUN and STAT3, were also post-transcriptionally more phosphorylated after VitD (Figs. 3g-h) . Thus, we reasoned that they are likely to play an important role in gene-regulation by VitD.

We carried out c-JUN CUT&RUN and VDR, STAT3 and BACH2 cleavage under target and Tagmentation (CUT&Tag) in VitD or carrier treated cells (Extended Data Fig.8a and Table S4 ) to identify genome-wide distribution of these TFs. Genome-wide binding of all four TFs was increased after VitD (Fig. 5a) , and they were recruited to H3K27Ac peak loci induced by VitD ( Fig. 5b and Extended Data Fig.8b ). VDR, c-JUN, STAT3 and BACH2 each bound ~20-40% of genes differentially expressed by VitD, significantly higher than other loci in the genome (Fig. 5c) . Indeed, ~60% of DEGs were bound by at least one of these TFs (Fig. 5d) , half of which were bound by more than one (Fig. 5e ). Genes bound by two or more TF included STAT3, IL10 and BACH2, (Fig. 5f ) indicating the complexity of gene regulation downstream of VitD exposure and interaction of multiple TFs within a gene regulatory network (Fig. 5g) . Collectively, these data showed reshaping of the epigenome by VitD, generating new and augmenting existing enhancers, and recruitment of transcriptional regulators to these loci to modify transcriptional output. BACH2, IL10 and STAT3 were exemplars of loci at which VDR binding generated new SEs, to which c-JUN, BACH2 and STAT3 were recruited ( Fig. 5h and Extended Data Figs.8c-d) and transcriptional output was increased (Figs. 3b-c).

We noted that STAT3 is directly bound by VDR (Figs. 5f-g and Extended Data Fig.8d ), but we did not find a CUT&Tag VDR peak proximal to the IL6 locus. This may be because IL6 is a lower affinity target, has a distal VDR binding site or because VDR binds this site earlier than the time point at which we carried out CUT&Tag. Thus, because ChIP-qPCR is more sensitive than genome-wide techniques when applied to individual loci, we performed qPCR for STAT3 and IL6 promoters, as well as CYP24A1 (a positive control locus), in anti-VDR ChIP fragments (Fig. 5i) . We found strong enrichment of CYP24A1 and STAT3 promoters and moderate enrichment of the IL6 promoter in anti-VDR ChIP fragments, indicating that these loci are all directly bound by VDR, and that VDR binding at IL6 is at lower affinity than the other two loci (Fig. 5i ). In summary, these data indicated VitD-induced dynamic changes in genome-wide enhancer architecture and recruitment of several TFs to loci that could explain ~60% of the VitD-dependent variance in gene expression.

BACH2 is a critical immunoregulatory TF 38, 39 . We confirmed that VitD induces BACH2 protein expression in Th cells (Fig. 6a) . Psoriatic skin is rich in CD4 + T cells, psoriasis severity is associated with low active VitD levels 40 and is frequently treated successfully with VitD 41 . We therefore performed confocal imaging on the dermis of patients with psoriasis treated, or not, with VitD. VitD-treatment significantly increased numbers of BACH2 + cells and greater numbers of intranuclear foci of BACH2, compared to untreated skin (Figs. 6b-e), confirming that BACH2 is induced by VitD in vivo. Genes regulated by VitD were ~2-3-fold enriched for BACH2 binding than those not regulated by VitD ( Fig. 6fg) . Indeed, BACH2-induced genes and BACH2-repressed genes were more highly expressed in VitD-treated and carrier-treated cells, respectively (Extended Data Figs.9a-b), indicating a BACH2 signature in VitD-regulated genes. Among the most highly enriched in the leading edge of BACH2-induced genes was the IL-6 receptor alpha chain (IL6R) (Extended Data Figs.9a and c). These observations suggested that a significant portion of VitD-driven transcription is BACH2-dependent. Thus, we compared transcriptomes of VitD-treated Th cells from healthy control (BACH2 WT/WT ) to those from a BACH2 haploinsufficient patient (BACH2 WT/L24P ) 36 . VitD-induced genes were significantly enriched in the transcriptomes of wildtype cells ( Fig. 6h and Table S5a ), indicating that normal BACH2 concentrations are required for appropriate regulation of VitD-induced genes (Extended Data Fig.9e ). The same pattern of enrichment was not found for VitD-repressed genes (Extended Data Fig.9d ), potentially indicating that half-normal concentrations of BACH2 are sufficient for repression of VitD targets. Thus, some, but not all, type 1 and type 17 inflammatory cytokines (IFNG and IL17F, but not IL17A) were repressed by VitD in BACH2 haploinsufficient cells (Extended Data Fig.9e and Table S5b ).

To better understand the VitD transcriptional regulatory network, we integrated VitD upand down-regulated genes in BACH2 WT/WT and BACH2 WT/L24P CD4 + T cells together with TF binding from CUT&Tag and CUT&RUN (Fig. 6i ). 75% and 66% of genes normally up-and down-regulated by VitD, respectively, were not regulated by VitD in BACH2 haploinsufficient cells. 28% and 14% of these, respectively, were directly bound by BACH2 (Fig. 6j ) and functionally annotated as cytokine and cytokine-cytokine receptor signaling genes, including IL6R and IL10 (Fig. 6k ). As noted, VitD promoted IL-10 via IL-6 signaling through IL-6R and STAT3 (Figs. 3f-j). Despite higher basal mRNA, IL6 was still induced by VitD when BACH2 levels were sub-normal, but IL10 was not, signifying that the IL-6-STAT3-IL-10 axis was disrupted in BACH2 haploinsufficiency (Figs. 6i-l and Extended Data Fig.9e ). Indeed, IL6R was not appropriately induced when BACH2 levels were sub-normal (Figs. 6i-l and Extended Data Fig.9e ). In animals, the IL6r gene is a direct genomic target of Bach2 and Bach2 knockout status significantly impairs the expression of Il6r (Extended Data Fig.9f ). Similar binding of this gene by BACH2 was evident in human cells (Fig. 6m) , presumably explaining why BACH2 haploinsufficiency impaired IL6R expression. Since BACH2 also binds IL10 (Fig. 5h) , it is likely that BACH2 deficiency also contributes directly to lower VitD-induced IL10 transcription. Collectively, these data indicate that BACH2 is a VitD-induced protein regulating a significant portion of the VitD transcriptome, with a key role in mechanisms that stimulate expression of IL-10.

There is compelling epidemiological association between incidence and severity of COVID-19 and VitD deficiency/insufficiency 19 , but the molecular mechanisms remain unknown. Given preferential Th1 polarization in COVID-19 BALF (Figs. 1d and Extended Data Fig.1e ), we hypothesized that VitD could be mechanistically important for hyperinflammation in COVID-19 and may be a therapeutic option. We studied expression of VitD-regulated genes ( Fig. 3a and Table S2b ) in COVID-19 BALF Th cells. Expression of VitD-repressed genes, summarized as module score, was significantly higher in patient Th cells than healthy controls (Fig. 7a) . This was further corroborated by Geneset enrichment analysis (GSEA) showing that genes more highly expressed in patient compared to control cells were enriched in VitD-repressed genes (Fig. 7b) . On a per cell basis the VitD-repressed module score correlated strongly with the Th1 score in BALF Th cells (Fig. 7c) , indicating a reciprocal relationship between Th1 genes and VitD-repressed genes. In contrast, VitDinduced genes were not substantially different (Extended Data Fig.10a ), nor were VitDregulated genes different in PBMC of patients compared to healthy donors (Extended Data Fig.10b ). To assess the ability of the Th1 and VitD-repressed gene signatures to distinguish patient from healthy BALF Th cells on a per cell basis, we constructed receiver operating characteristic (ROC) curves of the module scores. The area under the curve (AUC) for the two scores were 0.91 and 0.80, respectively (p<0.00001 for both) (Fig. 7d) . Thus, both Th1 and VitD-repressed gene signatures were strong features of COVID-19 BALF Th cells. To contextualize these performances, we calculated AUCs for module scores of every geneset in hallmark and canonical pathways curated by MSigDB (n=2279 genesets). The top performing sets were interferon responses, as expected. The performance of the VitDrepressed geneset was within the top 1% of all genesets ( Fig. 7e and Table S6 ), indicating that this was among the very best performing genesets. We then predicted significant drugs (among n=461) potentially able to counteract genes upregulated in COVID-19 BALF Th cells. Five of the top 10 most significant drugs were steroids and two were VitD (alfacalcidol) (Fig. 7f and Table S7 ). These were corroborated in independent datasets by GSEA, showing genes more highly expressed in lung biopsies or bulk BALF RNA-seq of COVID-19 compared to healthy control to be enriched in VitD-repressed genes (Figs. 7g-h). Significant numbers of genes modulated by VitD were shared by corticosteroid targets (Extended Data Fig.10c) . Steroids, including dexamethasone, increase transcription of VDR so may show therapeutic synergism with VitD. Collectively, these data suggest that, in Th cells from patients with severe COVID-19, the VitD-repressed geneset is de-repressed and that there may be clinical benefit from adding VitD to other immunomodulatory agents (Extended Data Fig.10d ).

We showed that cell-intrinsic complement orchestrates an autocrine/paracrine autoregulatory VitD loop to initiate Th1 shutdown. VitD causes genome-wide epigenetic re-modelling, induces and recruits TFs including STAT3, c-JUN and BACH2 that collectively repress Th1 and Th17 programs and induce IL-10 via IL-6-STAT3 signaling. This program is abnormal in lung Th cells of severe COVID-19, which show preferential Th1 skewing, and could be potentially exploited therapeutically by using VitD as an adjunct treatment.

IFN-γ-producing airway Th cells are key components of immunity to coronaviruses, including SARS-CoV1 and MERS-CoV 20 . Th1-polarized responses are also a feature of SARS-CoV2 in humans 24 and severe COVID-19 is accompanied by prolonged, exacerbated, circulating Th1 responses 21 . Complement receptor signaling is a driver of Th1 

Europe PMC Funders Author Manuscripts differentiation and required for effective anti-viral responses 12, 42 . C3 cleavage generates C3b, which binds CD46 on T cells. We have previously shown that the lungs in COVID-19 are a complement-rich micro-environment, that local CD4 + T lymphocytes have a CD46activated signature 13 , and show here that these T cells are Th1-polarized. Pro-inflammatory function is important for pathogen clearance, but a switch into IL-10 production is a natural component during successful transition into the Th1 shutdown program and reduces collateral damage 16 . Inability to produce IL-10 results in more efficient clearance of infections but severe tissue damage from uncontrolled Th1 responses results in death 2 . The benefits of remediating inflammatory pathways in severe COVID-19 is demonstrated by successful trials of dexamethasone, an immunosuppressive drug which reduces mortality 1 .

VitD has pleiotropic functions in the immune system, including anti-microbial as well as regulatory properties, which are cell-and context-dependent 43, 44 . VitD deficiency is associated with higher prevalence and worse outcomes from infections, including influenza, tuberculosis and viral upper respiratory tract illnesses 17 , as well as autoimmune diseases, including type 1 diabetes, multiple sclerosis, rheumatoid arthritis and inflammatory bowel disease 18 . Th cells play key roles in all these diseases. Thus, understanding VitD biology in Th cells has potential translational impact.

Our data indicate the complexities of TFs working within networks to regulate sets of genes. After VitD ligates VDR, c-JUN, STAT3 and BACH2 are recruited to acetylated loci, shaping the transcriptional response to VitD. c-JUN is a member of the AP-1 basic leucine zipper family, primarily involved in DNA transcription 45 . This TF was bound adjacent to 40% of VitD-regulated coding loci. BACH2 is a critical immunoregulatory TF 38, 39 downregulated in lesional versus non-lesional psoriatic skin 46 . Active VitD concentrations inversely correlate with severity of psoriasis 40 . We found that VitD-treatment of psoriatic lesional skin upregulated BACH2 expression. Both haploinsufficiency and single nucleotide variants of BACH2 associate with monogenic and polygenic autoimmunity, respectively, in humans 36, 47 . No BACH2 knock-out humans have yet been identified, suggesting incompatibility of complete BACH2 deficiency with life. Indeed, Bach2 -/mice succumb to fatal autoimmunity. We found that loss of even 50% of the normal cellular concentration of BACH2 in the haploinsufficient state substantially altered (~70% of) the VitD-regulated transcriptome. Since only a proportion of these genes were directly BACH2-bound, it is probable that BACH2 is a requisite for normal recruitment and function of the other transcriptional regulators.

Both the incidence and severity of COVID-19 are epidemiologically associated with VitD deficiency/insufficiency 19 , but the molecular mechanisms remain unknown. We found a link between the inflammatory Th1 program and a VitD-repressed geneset. Attempts to study CD4 + T cells from the site of inflammation were unsuccessful due to the rapid apoptosis of patient cells, but our in silico analyses suggest either dysregulation of the VitD program in COVID-19 or that simple deficiency/insufficiency of substrate (VitD) might explain the epidemiological association.

IL-6 is a pleiotropic, often pro-inflammatory, cytokine. IL-6 is implicated in the COVID-19 "cytokine storm" and targeting of this cytokine specifically have proved beneficial to patients 32 . Our data suggest that pro-inflammatory IL-6 functions may be redirected to production of anti-inflammatory IL-10 by VitD in activated human Th cells. VitD supplementation in children significantly increases serum IL-6 (and non-significantly increases in IL-10) 48 indicating that these observations may also occur in vivo. In the skin,

where VitD concentrations are high, IL-6 overexpression protects from injurious stimuli or infection 49 and IL-6-deficiency impairs wound healing 50 . Moreover, an adverse effect of anti-IL-6R for treating inflammatory arthritis is idiosyncratic development of psoriasis 51 , indicating a tolerogenic role for IL-6 at this site. Thus, adjunct VitD therapy in severe COVID-19 may divert pro-inflammatory and induce anti-inflammatory effects of IL-6, which may be an alternative to blocking IL-6R signalling.

These data identified the VitD pathway as a potential mechanism to accelerate shutdown of Th1 cells in severe COVID-19. From experience in other diseases, it is likely that VitD will be ineffective as monotherapy. Combination therapy could potentially ameliorate significant adverse effects of other drugs, e.g. high dose corticosteroids, including overimmunosuppression or metabolic side-effects. An important consideration of VitD therapy in COVID-19 is stimulation of IL-6 production from CD4 + T cells. Although autocrine/ paracrine IL-6 induces IL-10 in these cells, IL-6 could potentially have pro-inflammatory properties on other cells. These possibilities may be mitigated by adding VitD as an adjunct to other immunomodulators, such as corticosteroids or JAK inhibitors 13 . Of note, two randomized clinical trials with calcifediol, a VitD analogue with high bioavailability not requiring hepatic 25-hydroxylation, comprising >1000 patients together, reported reductions in risk of ICU admission or death when used in addition to standard care (OR of 0.13 and 0.22, respectively 52,53 ). These findings are not necessarily specific to COVID-19, since VitD can protect against acute respiratory tract infections in general 17 .

In conclusion, we identified an autocrine/paracrine VitD loop permitting Th1 cells to both activate and respond to VitD as part of a shut-down program repressing IFN-γ and enhancing IL-10. These events involved significant epigenetic re-shaping and recruitment of a network of key TFs. These pathways could potentially be exploited therapeutically to accelerate the shut-down program of hyper-inflammatory cells in patients with severe COVID-19.

Human studies, conducted in accordance with the Declaration of Helsinki, were approved by the Institutional Review Board of Guy's Hospital (reference 09/H0707/86), National Institutes of Health (approval numbers 7458, PACI, 13-H-0065 and 00-I-0159) and Imperial College London (approval number 12/WA/0196 ICHTB HTA license number 12275 to project R14098). All patients provided informed written consent.

Human PBMCs were purified from anonymized leukodepletion cones (Blood Transfusion Service, NHS Blood and Transplantation) or healthy volunteer whole blood packs/buffy coats from the NIH Blood Bank and from fresh patient blood. Leukodepletion cones were diluted 1 in 4 with PBS and layered onto Lymphoprep (Axis-Shield). Whole blood packs/ buffy coats were diluted 1 in 2 with PBS onto Lymphocyte Separation Medium (25-072-CV LSM, Corning) and centrifuged.

CD4 + CD25 − cells were used throughout, unless specified. CD4 + T cells were enriched using RosetteSep Human CD4 + enrichment cocktail (Stem Cell) with CD4 + CD25 − cells obtained by depletion of CD25 + T cells using CD25 positive selection (CD25 microbeads II, Human, Miltenyi Biotec) followed by unlabeled cell collection. Human memory CD4 + T cells were used for RNA-seq, CUT&RUN and CUT&Tag experiments as these cells express the VDR. These cells were isolated from PBMCs using Miltenyi Memory CD4 + T cell Isolation Kit Human (130091893) 

Proteome Profiler Human Phospho-Kinase Array (R&D systems) was carried out on VitD-or carrier-treated CD4 + cells. Cells were lyzed in manufacturer's buffer, protein concentrations quantified by Quick Start Bradford Protein Assay (BioRad) and samples adjusted to 800μg/mL with lysis buffer. 334μL were loaded per membrane and signals amplified by Chemi-Reagent Mix imaged (ImageQuant LAS 4000 mini) and quantified (Image Studio Lite). Reference spots were used to normalize signals across membranes.

VDR and DAPI colocalization was performed in CD4 + T cells stained with VDR antibody (1:250, D-6), anti-mouse-AlexaFluor647 (1:400, clone poly4053, BioLegend) and DAPI. Images were acquired via ImageStreamX running Inspire and VDR to DAPI colocalization assessed (IDEAS/v3.0, Amnis). A minimum of 1x10 5 events were acquired per sample. 

Europe PMC Funders Author Manuscripts Scientific). Comparative Ct method was used for analysis using the Viia7 software producing a Ct (relative quantity (RQ) compared to a reference sample).

For STAT3 siRNA, memory CD4 + T cells were sorted and rested overnight in culture medium. 5x10 6 cells were washed twice with PBS and nucleofected with 10nM STAT3 silencer select siRNA (s745, sense GCACCUUCCUGCUAAGAUUTT and antisense AAUCUUAGCAGGAAGGUGCCT) or Silencer Select Negative Control (Thermo Fisher Scientific) using the Amaxa Human T Cell Nucleofector Kit (Nucleofector 2b Device, U-014 program, Lonza). Nucleofected cells were cultured in media for 6h followed by dead cell removal (Lymphoprep, Axis-Shield). 2x10 6 recovered cells were activated with anti-CD3/CD28 beads for 72h and knock-down assessed by western.

For chemical STAT3 inhibition, memory CD4 + T cells were sorted and rested overnight. H3K27Ac reads aligned to the human reference genome (GRCh37; hg19) using Bowtie2 56 with parameters '--local --maxins 250' with sorting and indexing of aligned reads by samtools/1.10 57 , reads with mapping quality <30 removed. H3K27Ac peaks were called by MACS2 58 with parameter '-f BAMPE --nomodel'. JUN reads were mapped without '--local' parameter. <120 bp fragments were further sorted and indexed by samtools/1.10 57 . JUN induced peaks called by MACS2 parameters '--nomodel -g hs -f BAMPE -q 0.01 --SPMR --keep-dup all'. IgG BAM files were included as controls for MACS2. Peaks for H3K27Ac and JUN experiments were screened against previously characterized hypersequencableregions (Hg19 Blacklist, CutRunTools 59 ). H3K27ac and JUN mean binding intensities in peak regions calculated by UCSC bigWigAverageOverBed. Peaks, combined from two conditions, with mean binding intensity greater than 0.2 in at least one condition and fold change of signal>1.5 were differential. Known motifs +/−100bp from differential peak summits were identified (HOMER, findMotifsGenome.pl, parameter '-size given'). De novo motif footprinting for c-JUN was performed (CutRunTools 74 ). Average cuts per bp proximal to JUN peaks was plotted as a histogram relative to IgG. CUT&RUN tracks and heatmaps were visualized using IGV (Broad Institute) and deepTools 60 , respectively.

Super-Enhancers were called using ROSE (Rank Ordering of Super-Enhancers) 37 

ChIP-PCR detection of VDR binding at the promoters of CYP24A1, STAT3, and IL-6 was determined from 2x10 5 CD4 + cells activated with VitD or Carrier for 48h followed by True MicroChIP (C01010132, Diagenode, 3 bioruptions/sample). 4μg of anti-VDR (D-6) or IgG2a isotype control antibody (E5Y6Q, Cell Signaling Technologies) was used during overnight chromatin precipitation at 4C before reverse-crosslinking and purification (MicroChIP DiaPure, Diagenode). qPCR primers were designed to amplify regions within 500bp upstream of the transcriptional start site for each respective gene: CYP24A1 (F: TGACCGGGGCTATGTTCG, R: GGCTTCGCATGACTTCCTG); STAT3 (F: CTGTTCCGACAGTTCGGTGC, R: GCAGGACATTCCGGTCATCTTC); and IL-6 (F: GTAAAACTTCGTGCATGACTTCAGC, R: GGGGGAAAAGTGCAGCTTAGG).

Triplicate qPCR using POWRUP SYBR Green (Thermo Fisher) was quantified via CFX384 (Bio-Rad), and results calculated as %Input= 2 (-ΔCt [normalized ChIP]) .

Memory CD4 + T cells, including from BACH2 WT/L24P patients, were activated with VitD or carrier. 6x10 5 cells were pelleted at 300g for 5 min and RNA extracted by RNAqeous Micro (Thermo Fisher Scientific). 1μg total RNA for each sample was subjected to NEBNext Poly(A) mRNA Magnetic Isolation (E7490) and resulting mRNA prepared for RNA-seq by NEB Ultra II (New England Biolabs) and sequenced by HiSeq (Illumina).

The expression levels of all genes in RNA-seq libraries were quantified by 'rsem-calculateexpression' in RSEM/v1.3.1 62 with parameters '--bowtie-n 1 --bowtie-m 100 --seed-length 28 --bowtie-chunkmbs 1000'. The bowtie index for RSEM alignment was generated by 'rsem-prepare-reference' on all RefSeq genes, downloaded from UCSC table browser in April 2017. EdgeR/v3.26.8 63 was used to normalize gene expression among all libraries and identify DEGs among samples. Microarray analysis sourced from GSE119416 was carried out using Partek Genomics Suite (Partek, Inc.). DEGs were defined using the following criteria: at least 1.5-fold change in either direction at p-value<0.05 for microarray; at least 1.75-fold change in either direction at FDR<0.05 for RNA-seq.

The pre-processed h5 matrix files for nine COVID-19 patient bronchoalveolar-lavage (BAL) samples and four healthy control BAL samples were from GSE145926 64 and GSE122960 65 , and GSM3660650, respectively. Read mapping and basic filtering performed with Cell Ranger (10x Genomics). Further processing using Seurat/v3 66 as follows: Only genes found to be expressed in more than 3 cells and cells with gene number between 200 and 6,000 (UMI count >1,000) retained. Cells with >10% of their unique molecular identifiers (UMIs) mapping to mitochondrial genes or cells with <300 features discarded to eliminate low quality cells. Filtering yielded 66453 cells across 12 samples. Filtered count matrices were normalized by total UMI counts, multiplied by 10,000 and transformed to natural log space. Top 2000 variable features determined by the variance stabilizing transformation function (FindVariableFeatures) using default parameters. All integrated using canonical correlation analysis (FindIntegrationAnchors/IntegrateData) with parameter k.filter=140 67 . Variants arising from library size and percentage of mitochondrial genes regressed out (ScaleData, Seurat). Principal Component Analysis (PCA) was performed, and the top 50 Principal Components (PCs) were included in a Uniform Manifold Approximation and Projection (UMAP). Clusters identified on a shared nearest neighbor (SNN) modularity graph using the top 50 PCs and the original Louvain algorithm. Cluster annotations are based on canonical marker genes.

Cells identified as "T" and "Cytotoxic T" were subsetted and reprocessed. Samples C146 and C52 were removed due to low T cells (19 and 56 cells, respectively). Integration was performed using FindIntegrationAnchors/IntegrateData with parameters: "dims=1:30 k.filter=124". Normalization, variable feature detection, scaling, dimensionality reduction, and clustering performed using the top 30 PCs and clustering resolution of 0.3. Annotation guided by marker genes (Extended Data Fig.1c) . The contaminating macrophage cluster annotated by canonical marker genes (e.g. CD14) was removed. Statistical differences were assessed by two-tailed Wilcoxon test. DEGs were defined by fold change of >1.5, adjusted p value of <0.05 and expression in at least 10% of cells in either cluster comparison.

Two clusters annotated as CD4 + T cells, one with few cells but expressed similar markers to the main CD4 + cluster. The two were combined and considered together for analysis. DEGs between COVID-19 and Healthy CD4 + T cells were visualized using Morpheus (https:// software.broadinstitute.org/morpheus/). DEGs upregulated in COVID-19 CD4 + T cells were subjected to pathway analysis (Fig. 1c) using the hallmark geneset collection from the Molecular Signatures Database (MSigDB/v7.1) or drug prediction from the National Toxicology Program's DrugMatrix genesets (n=7876) using EnrichR (Fig. 4f) . Gene list scores calculated by the AddModuleScore function in Seurat with a control gene set (n of 100). The correlation and the ROC analyses on the module scores comparing patients and healthy controls performed in R or Prism/v8.4.0.

The pre-processed R objects for six COVID-19 patient PBMC samples and six healthy control PBMC samples were from GSE150728 68 with read mapping and filtering by Cell Ranger. The exon count matrices were further processed by Seurat as follows: Only genes found to be expressed in more than 10 cells were retained. QC steps for filtering the samples as described 68 . Cells with 1,000-15,000 UMIs and <20% of reads from mitochondrial genes were retained. Cells with >20% of reads mapped to RNA18S5 or RNA28S5, and/or expressed >75 genes per 100 UMIs excluded. SCTransform function normalized the dataset and identified variable genes 68 . PCA was performed and top 50 PCs were included in UMAP dimensionality reduction. Clusters were identified on a SNN modularity graph using the top 50 PCs and the original Louvain algorithm. Cluster annotations were based on canonical marker genes. Gene list module scores were calculated by the AddModuleScore function in Seurat 66 . AUCs for module scores of every geneset in hallmark and canonical pathways curated by MSigDB (n=2279 genesets) [69] [70] [71] .

GSEA was carried out as published 69 . Tr1 gene lists were obtained from GSE139990. Data were filtered to include only genes expressed at greater than 0.25 counts per million in at least 2 samples, TMM normalized within the edgeR/v3.28.1, and differential expression performed using the glmQLFit and glmQLFTest edgeR functions. Tr1 signatures defined as DE genes (at least 4-fold change in either direction at FDR<0.05) between Tr1 and Th0 cells. Th1/Th2/Th17 gene lists obtained from transcriptomes of sorted mouse CD4 + T cell subsets 72 . VitD-regulated genes defined as described in RNA-seq methods. BACH2 bound and regulated genes obtained from GSE45975 38 . All gene lists used in this manuscript are in Table S8 .

Informed consent for all psoriasis patients and data was obtained under the Psoriasis, Atherosclerosis and Cardiometabolic Disease Initiative (PACI, 13-H-0065). Samples included 3 psoriasis patients not on VitD and 2 psoriasis patients on VitD supplementation. 3 mm punch-biopsies were collected from psoriasis lesional skin and placed into 10% formalin. 7μm skin sections were mounted on glass slides, de-waxed, and antigens-retrieved Shown are cumulative data from n=3 independent experiments. Bars show mean + sem. NT, non-targeting. **p<0.01 ***p<0.001 by unpaired two-sided t-test. Table S7 . d, Schematic model of autocrine VitD-driven Th1 contraction program and potential intervention of impaired COVID-19 program with VitD and cortico-steroids. e, representative flow sorting strategy and example of post-sort purity obtained for isolation of memory CD4 + T cells in this paper.

Refer to Web version on PubMed Central for supplementary material. 

Dexamethasone in Hospitalized Patients with Covid-19

In the absence of endogenous IL-10, mice acutely infected with Toxoplasma gondii succumb to a lethal immune response dependent on CD4+ T cells and accompanied by overproduction of IL-12, IFN-gamma and TNF-alpha

Overview of Complement Activation and Regulation

Complement System Part I -Molecular Mechanisms of Activation and Regulation

Activation of the Complement System in the Adult Respiratory Distress Syndrome1-4

Serum concentrations of complement anaphylatoxins and proinflammatory mediators in patients with 2009 H1N1 influenza

Association of COVID-19 inflammation with activation of the C5a-C5aR1 axis

Complement Overactivation and Consumption Predicts In-Hospital Mortality in SARS-CoV-2 Infection. Front Immunol

Immune complement and coagulation dysfunction in adverse outcomes of SARS-CoV-2 infection

Early Upregulation of Acute Respiratory Distress Syndrome-Associated Cytokines Promotes Lethal Disease in an Aged-Mouse Model of Severe Acute Respiratory Syndrome Coronavirus Infection

The first case of COVID-19 treated with the complement C3 inhibitor AMY-101

Intracellular Complement Activation Sustains T Cell Homeostasis and Mediates Effector Differentiation

SARS-CoV-2 drives JAK1/2-dependent local complement hyperactivation

Complement and the Regulation of T Cell Responses

Aberrant type 1 immunity drives susceptibility to mucosal fungal infections

Complement regulator CD46 temporally regulates cytokine production by conventional and unconventional T cells

Vitamin D for Treatment and Prevention of Infectious Diseases: A Systematic Review of Randomized Controlled Trials

Low Serum 25-hydroxyvitamin D (Vitamin D) Level Is Associated With Susceptibility to COVID-19, Severity, and Mortality: A Systematic Review and Meta-Analysis

Airway Memory CD4(+) T Cells Mediate Protective Immunity against Emerging Respiratory Coronaviruses

Longitudinal analyses reveal immunological misfiring in severe COVID-19

Diapedesis-Induced Integrin Signaling via LFA-1 Facilitates Tissue Immunity by Inducing Intrinsic Complement C3 Expression in Immune Cells

Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five cases

Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals

DCs metabolize sunlight-induced vitamin D3 to "program" T cell attraction to the epidermal chemokine CCL27

Expression of 1,25-Dihydroxyvitamin D3 Receptor in the Immune System

Altered microRNAs expression in T cells of patients with SLE involved in the lack of vitamin D

1,25-Dihydroxyvitamin D3 and IL-2 Combine to Inhibit T Cell Production of Inflammatory Cytokines and Promote Development of Regulatory T Cells Expressing CTLA-4 and FoxP3

In Vitro Generation of Interleukin 10-producing Regulatory CD4+ T Cells Is Induced by Immunosuppressive Drugs and Inhibited by T Helper Type 1 (Th1)-and Th2-inducing Cytokines

Coexpression of CD49b and LAG-3 identifies human and mouse T regulatory type 1 cells

IL-6 as a keystone cytokine in health and disease

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Interleukins 27 and 6 induce STAT3-mediated T cell production of interleukin 10

Interleukin-6 induces the generation of IL-10-producing Tr1 cells and suppresses autoimmune tissue inflammation

Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells

BACH2 immunodeficiency illustrates an association between super-enhancers and haploinsufficiency

Master Transcription Factors and Mediator Establish Super-Enhancers at Key Cell Identity Genes

BACH2 represses effector programs to stabilize T(reg)-mediated immune homeostasis

Human retinoic acid-regulated CD161+ regulatory T cells support wound repair in intestinal mucosa

Serum active 1,25(OH)2D, but not inactive 25(OH)D vitamin D levels are associated with cardiometabolic and cardiovascular disease risk in psoriasis

Clinical Presentation, and Treatment of Psoriasis

Human complement C3 deficiency: Th1 induction requires T cell-derived complement C3a and CD46 activation

1,25D3 prevents CD8+Tc2 skewing and asthma development through VDR binding changes to the Cyp11a1 promoter

Vitamin D receptor restricts T helper 2-biased inflammation in the heart

Human proto-oncogene c-jun encodes a DNA binding protein with structural and functional properties of transcription factor AP-1

Meta-Analysis Derived (MAD) Transcriptome of Psoriasis Defines the "Core

Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci

Effects of Vitamin D Supplementation and Seasonality on Circulating Cytokines in Adolescents: Analysis of Data From a Feasibility Trial in Mongolia

Interleukin 6: insights to its function in skin by overexpression in transgenic mice

Essential involvement of IL-6 in the skin wound-healing process as evidenced by delayed wound healing in IL-6-deficient mice

Psoriasis Onset with Tocilizumab Treatment for Rheumatoid Arthritis

Calcifediol treatment and COVID-19-related outcomes

Calcifediol Treatment and Hospital Mortality Due to COVID-19: A Cohort Study

Complement Regulates Nutrient Influx and Metabolic Reprogramming during Th1 Cell Responses

Targeted in situ genome-wide profiling with high efficiency for low cell numbers

Fast gapped-read alignment with Bowtie 2

The Sequence Alignment/Map format and SAMtools

Model-based Analysis of ChIP-Seq (MACS)

CUT&RUNTools: a flexible pipeline for CUT&RUN processing and footprint analysis

deepTools2: a next generation web server for deep-sequencing data analysis

CUT&Tag for efficient epigenomic profiling of small samples and single cells

RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome

edgeR: a Bioconductor package for differential expression analysis of digital gene expression data

Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19

Single-Cell Transcriptomic Analysis of Human Lung Provides Insights into the Pathobiology of Pulmonary Fibrosis

Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq

Comprehensive Integration of Single-Cell Data

A single-cell atlas of the peripheral immune response in patients with severe COVID-19

Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles

Molecular signatures database (MSigDB) 3.0

The Molecular Signatures Database Hallmark Gene Set Collection

An atlas of mouse CD4+ T cell transcriptomes

Cytoscape: A Software Environment for Integrated Models of Biomolecular Interaction Networks

Circos: An information aesthetic for comparative genomics

Author manuscript; available in PMC

Shown are Benjamini-Hochberg adjusted p-values from hypergeometric tests. f, VDR (left panel) and CYP27B1 (right panel) mRNA in Th cells activated, or not, as indicated, with or without cathepsin L inhibitor (CTSL inh.) (n=5 experiments). g, VDR (left panel) and CYP27B1 (right panel) mRNA in Th cells of a patient with CD46-deficiency, activated, or not, as indicated (n=3 experiments). h-i, Representative flow cytometry (h) and cumulative data from n=6 independent experiments (i) showing IFN-γ and IL-10 in Th cells activated with α-CD3+α-CD46 with

Author manuscript; available in PMC

Heatmap scale indicates fold change expression after VitD treatment compared to Carrier. h, Genome browser tracks at the BACH2 and IL10 loci showing H3K27Ac, c-JUN, BACH2, STAT3 and VDR binding in Carrier and VitD-treated cells. Red and blue dots represent peaks in Carrier and VitD-treated cells, respectively. SE denotes super-enhancer regions. Track heights are indicated on the left corner for each track. i, ChIP-qPCR for VDR or IgG in VitD-treated Th cells from two donors. Anti-VDR ChIP fragments were probed by qPCR for

Data are shown separately for each donor; bars show mean+sem of qPCR. All p-values are from two-sided tests

Author manuscript; available in PMC

Shown is a representative example from n=3 experiments. b-e, Representative dermal images of lesional skin from psoriasis patients with (n=2) and without (n=3) VitD supplementation stained for BACH2 (red) and CD3 (green), showing overview (leftmost) and zoomed images (right three images) (b), number of nuclei/image (c), percentage of BACH2 + cells relative to nuclei frequency/image (d) and average number of BACH2 foci/cell (e)

Author manuscript; available in PMC

Pie-charts comparing percentage of VitD-regulated genes bound and regulated by mouse (f) or human BACH2 (g) against all genes in the genome. The two-sided Fisher exact p-value is shown. h, GSEA showing enrichment in VitD-induced genes comparing transcriptomes of VitD-treated wild-type control (BACH2 WT/WT ) with BACH2-haploinsufficient Th cells (BACH2 WT/L24P )

Pie-charts comparing percentage of genes up-and down-regulated by VitD in BACH2 sufficient cells that are differently regulated in BACH2-haploinsufficiency. The percentage of those genes bound by BACH2 are shown underneath. k, Top 3 enriched MSigDB canonical pathways pertaining to the genes bound by BACH2 and differently regulated in BACH2-haploinsufficient cells. Indicated are 3 relevant genes contributing to enriched pathways. l, Heatmap showing expression patterns of select VitD-regulated genes in the transcriptomes of carrier-and VitD-treated BACH2 WT/WT and BACH2 WT/L24P Th cells. m, Genome browser tracks at IL6R locus showing H3K27Ac, c-JUN, BACH2, STAT3 and VDR binding in Carrier and VitD-treated cells. Red and blue dots represent peaks in Carrier and VitDtreated cells, respectively. Track heights are indicated on the left

Author manuscript; available in PMC

Marked are the top 2 performing genesets in red and the position of the VitD-repressed geneset within the top 1% of all genesets. f, Top 10 drugs predicted (out of 461 significant drugs) to counteract genes induced in BALF Th cells of COVID-19 patients compared to healthy controls, ordered by adjusted p-value. Highlighted in red is alfacalcidol, an FDA-approved active form of VitD. g-h, GSEA showing enrichment in VitD-repressed genes for genes more highly expressed in bulk RNA-seq lung biopsy specimens (g) and bulk RNA-seq BALF cells (h) of COVID-19 compared to healthy controls

NES = normalized expression value. p-values in d are from the Mann-Whitney U-statistic. Data in a-f are from n=8 patients with COVID-19 and n=3 healthy controls, sourced from GSE145926 and GSE122960. Data in g-h are from GSE147507 and HRA000143, respectively

The authors thank patients who contributed samples toward this study. We would like to acknowledge Gennady Denisov and the NIH HPC (Biowulf) for their efforts in maintaining essential bioinformatic programs. We would like to thank Qian Zhu, Nan Liu, Derek Janssens, and Steven Henikoff for critical discussions related to CUT&RUN experimentation and data analysis. 

Data generated for this study are deposited at the Gene Expression Omnibus (GEO) under GSE154741.